Is CJC-1295/Ipamorelin FDA Approved? What You Need to Know

The Short Answer

CJC-1295 and Ipamorelin are not FDA-approved drugs. They never completed the full clinical trial process required for FDA approval. That does not mean they are illegal, unregulated, or unsafe. It means they exist in a different regulatory category: compounded medications.

When your provider prescribes CJC-1295/Ipamorelin, a licensed compounding pharmacy prepares it specifically for you. This is the same regulatory framework used for thousands of other compounded medications that millions of Americans use every day. Compounding pharmacies are regulated by state boards of pharmacy, and 503B outsourcing facilities are additionally inspected by the FDA.

What FDA Approval Actually Means

FDA approval is a specific regulatory process. A pharmaceutical company sponsors a drug through preclinical testing, Phase 1 (safety), Phase 2 (dosing and efficacy), and Phase 3 (large-scale efficacy) clinical trials. The company then submits a New Drug Application (NDA) with manufacturing data, labeling, and post-market surveillance plans. The entire process typically takes 10 to 15 years and costs $1 billion or more.

FDA approval proves that a specific formulation, at a specific dose, for a specific indication, met the endpoints in controlled clinical trials. It does not mean the drug is safe for everyone. It does not mean unapproved drugs are unsafe. It means one company invested the resources to run that specific gauntlet for a specific commercial product.

Many widely used medications were never FDA-approved for the conditions they treat. Off-label prescribing accounts for roughly 20% of all prescriptions written in the United States. Compounded medications occupy another category entirely: they are prepared under pharmacy law, not drug approval law.

How Compounded Peptides Work

The legal framework for compounding comes from Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These provisions allow licensed pharmacies to prepare medications that are not commercially available as FDA-approved products, based on a valid prescription from a licensed provider.

PeRx works with licensed compounding pharmacies that meet or exceed these standards. Every vial undergoes potency testing, sterility testing, and endotoxin testing before it ships to a patient. The pharmacy is licensed, the provider is licensed, and the prescription is patient-specific.

The One Growth Hormone Peptide That Is FDA Approved

If FDA approval matters to you, there is one growth hormone peptide that has it: Tesamorelin. Sold under the brand name Egrifta, Tesamorelin was approved by the FDA in November 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Tesamorelin earned its approval through two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials (LIPO-010 and LIPO-011) enrolling 816 patients. Results showed a 15% reduction in visceral adipose tissue over 26 weeks, measured by CT scan. It is the only GHRH analog that has completed this process.

What the Clinical Evidence Shows

The fact that CJC-1295/Ipamorelin lacks FDA approval does not mean it lacks clinical evidence. Both peptides have been studied in human trials, and their mechanisms of action are well characterized.

CJC-1295 (Modified GRF 1-29)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), modified with a Drug Affinity Complex (DAC) that extends its half-life from minutes to days. In a Phase 2 clinical trial, CJC-1295 produced dose-dependent increases in growth hormone and IGF-1 levels in healthy adults aged 21 to 61. Mean IGF-1 levels increased by 35-85% depending on dose, sustained for 6 or more days after a single injection. The trial found it was well tolerated with injection site reactions as the most common side effect.

Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006. View study

Ipamorelin

Ipamorelin was developed by Novo Nordisk as a selective growth hormone secretagogue. Unlike earlier GH secretagogues like GHRP-6, Ipamorelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels. This selectivity is why it became the preferred pairing with CJC-1295. Animal studies showed dose-dependent GH release comparable to GHRP-6 but with a cleaner side effect profile. Human pharmacokinetic data confirmed consistent GH pulsatility.

Raun K et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998. View study

Why the Combination

CJC-1295 provides the sustained baseline signal through the GHRH receptor. Ipamorelin amplifies each individual pulse through the ghrelin receptor. They act on two different receptor systems, which is why the combination produces a synergistic effect greater than either peptide alone. The pairing preserves the body's natural somatostatin feedback loop, producing physiological GH patterns rather than the flat, sustained elevation you get from injecting growth hormone directly.

What to Look For in a Provider

Because CJC-1295/Ipamorelin is compounded rather than commercially manufactured, the quality of your experience depends heavily on two things: your provider and your pharmacy. Not all compounding pharmacies operate at the same standard. Not all providers have the same level of expertise with peptide therapy.

Here is what to look for:

Provider credentials. Your prescriber should be a licensed physician, nurse practitioner, or physician assistant authorized to prescribe in your state. They should have specific training or experience with peptide therapy and growth hormone optimization. They should order baseline labs (IGF-1 at minimum) and monitor your progress.

Pharmacy quality. The compounding pharmacy should be state-licensed at minimum. Look for 503B outsourcing facility status (FDA-registered and inspected) or PCAB accreditation. Every batch should undergo potency testing, sterility testing, and endotoxin testing. Ask for a Certificate of Analysis (COA) if you want to verify.

Product format. Your peptides should arrive fully reconstituted and ready to use. If a provider is shipping you lyophilized powder and telling you to mix it yourself with bacteriostatic water, that is an outdated practice that introduces unnecessary contamination risk. PeRx ships all peptides pre-mixed, tested, and ready for injection.

Frequently Asked Questions